智通财经网·2025-09-26 09:34Core Viewpoint - Fosun Pharma (600196.SH) is planning to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, intends to invest RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's assets after full fundraising [1] - The subsidiary plans to transfer its 100% equity in Shanghai Clone and related debts to the special fund or its controlled entities for no more than RMB 1.256 billion after the fund is established and conditions are met [1] - Following the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property as an operating site, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - The proceeds from this transfer will be utilized for continued investment in the group's innovative drug business [1]